EUVIMEDEUVIMED entdecken
Open Access

Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV

Nicole H Tobin iD, Sarah L Brooker, Fan Li, Robert W Coombs iD, Susan E Cohn, Laura Moran, Mey Leon, Nuntisa Chotirosniramit, Emilia M Jalil, Unoda A Chakalisa iD, Kimberly K Scarsi, Carmen D Zorrilla und 2 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Nicole H Tobin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Vagina, HIV Infections, Desogestrel, Ethinyl Estradiol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human immunodeficiency virus 1 (HIV-1) antiretroviral therapy (ART) alters hormonal contraceptive levels delivered via intravaginal ring (IVR) in a regimen-specific manner. We explored the role of the IVR on vaginal microbial communities, vaginal short chain fatty acids (SCFAs), vaginal HIV shedding, and the effect of vaginal microbes on hormone concentrations in cisgender women with HIV (WWH).

Methods

Vaginal microbes were assessed by 16S RNA sequencing of weekly vaginal swabs, vaginal SCFA by mass spectrometry, HIV-1 shedding by nucleic acid amplification on vaginal aspirates, and bacterial vaginosis by Nugent scoring from 74 participants receiving an etonogestrel/ethinyl estradiol (ENG/EE) intravaginal ring while on no ART (n = 25), efavirenz-based ART (n = 25), or atazanavir-based ART (n = 24).

Results

At baseline, microbial communities of the 64 substudy eligible participants robustly classified as Lactobacillus crispatus-dominant (n = 8), Lactobacillus gasseri-dominant (n = 2), Lactobacillus iners-dominant (n = 17), or mixed anaerobic communities (n = 37). During IVR therapy, there was an increased probability of Lactobacillus-dominant community state types (CSTs) (odds ratio = 1.61, P = .04). Vaginal CSTs were associated with Nugent scores. Bacterial vaginosis-associated bacteria were associated with significantly higher and L. iners with lower Nugent scores (all P adjusted <.1). Lactic acid levels were correlated with the relative abundance of Lactobacillus species (r2 = 0.574; P < .001). Vaginal shedding of HIV-1 was less common in women with L. crispatus-dominant microbiomes (P = .04). Mixed anaerobic vaginal communities modulated EE concentrations in a regimen-specific manner.

Conclusions

Combined ENG/EE IVR therapy was associated with an increase in Lactobacillus-dominant vaginal microbial communities in WWH and may benefit those with bacterial vaginosis. EE levels were altered by the vaginal microbiota.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VaginaHIV InfectionsDesogestrelEthinyl EstradiolContraceptive Devices, FemaleMicrobiotaContraceptive Agents, FemaleHumansFemaleAdultHIV-1Virus SheddingVaginosis, BacterialMiddle Aged

Stichwörter der Autor:innen

HIV transmissioncontraceptive therapyintravaginal ringvaginal microbiome

Substanzen

DesogestrelEthinyl EstradioletonogestrelContraceptive Agents, Female

Autor:innen und Institutionen

  • Department of Pediatrics, University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Public Health and Scientific Research Unit, Social and Scientific Systems, DLH Corporation, Silver Spring, Maryland, USA.
  • Investigator Barranco Clinical Research Site, PERU Clinical Trials Unit Asociación Civil IMPACTA Salud y Educación, Barranco Clinical Research Site, Lima, Peru.

ORCID-Profile: Nicole H Tobin, Robert W Coombs, Unoda A Chakalisa

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NICHD NIH HHS
  • Office of Research on Women's Health
  • NIMH NIH HHS
  • NIH HHS
  • NIH
  • AIDS Clinical Trials Group

Zitieren

APA

Tobin, N. H., Brooker, S. L., Li, F., Coombs, R. W., Cohn, S. E., Moran, L., Leon, M., Chotirosniramit, N., Jalil, E. M., Chakalisa, U. A., Scarsi, K. K., Zorrilla, C. D., Godfrey, C., & Aldrovandi, G. M. (2025). Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae524

Vancouver

Tobin NH, Brooker SL, Li F, Coombs RW, Cohn SE, Moran L, et al. Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae524

BibTeX
@article{Tobin2025,
  author = {Tobin, Nicole H and Brooker, Sarah L and Li, Fan and Coombs, Robert W and Cohn, Susan E and Moran, Laura and Leon, Mey and Chotirosniramit, Nuntisa and Jalil, Emilia M and Chakalisa, Unoda A and Scarsi, Kimberly K and Zorrilla, Carmen D and Godfrey, Catherine and Aldrovandi, Grace M},
  title = {Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae524}
}
Kostenlos starten →